Executive Separation: Social media discussions highlight Hepion Pharmaceuticals' recent agreement with its former CEO, involving a $225,000 payment amid a director's resignation. The company maintains nine active clinical trials despite the leadership shift. Investors note this as part of ongoing transitions in the biotech space.
Diagnostic Licensing Deal: Chatter focuses on Hepion's March in-licensing of a ctRNA biomarker assay from Cirna Diagnostics for early hepatocellular carcinoma detection. This move signals a pivot toward liquid biopsy diagnostics after winding down prior therapeutic development. Participants view it as a strategic shift to bolster its portfolio amid funding constraints.
Financial Outlook: Conversations underscore Hepion's limited cash runway into Q3 2026, prompting emphasis on new financing needs. The firm has expanded diagnostics through multiple licenses, including for celiac and liver tests. Sentiment reflects cautious interest in its evolving business model.
Note: This discussion summary was generated from an AI condensation of post data.
Hepion Pharmaceuticals Insider Trading Activity
Hepion Pharmaceuticals insiders have traded $HEPA stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $HEPA stock by insiders over the last 6 months:
- VINCENT S LOPRIORE (Executive Chairman) has made 2 purchases buying 6,250,000 shares for an estimated $250,000 and 0 sales.
- GARY S. STETZ (Interim CEO) purchased 1,250,000 shares for an estimated $50,000
- SIREESH APPAJOSYULA purchased 1,250,000 shares for an estimated $50,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Hepion Pharmaceuticals Hedge Fund Activity
We have seen 0 institutional investors add shares of Hepion Pharmaceuticals stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ANCORA ADVISORS LLC added 0 shares (+0.0%) to their portfolio in Q4 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
